ଜେମସାଇଟାବିନ

ଜେମସାଇଟାବିନ
Clinical data
Pronunciation	jem-SEYE-tə-been
Trade names	Gemzar, others
AHFS/Drugs.com	monograph
Pregnancy; category	AU: D ; US: D (Evidence of risk) ; ;
Routes of; administration	Intravenous
ATC code	L01BC05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; ℞ (Prescription only);
Pharmacokinetic data
Protein binding	<10%
Elimination half-life	Short infusions: 32–94 minutes; Long infusions: 245–638 minutes
Identifiers
	IUPAC name 4-Amino-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidin-2(1H)-on;
CAS Number	95058-81-4 ;
PubChem CID	60750;
IUPHAR/BPS	4793;
DrugBank	DB00441 ;
ChemSpider	54753 ;
UNII	B76N6SBZ8R;
KEGG	D02368 ;
ChEBI	CHEBI:175901 ;
ChEMBL	CHEMBL888 ;
ECHA InfoCard	100.124.343
Chemical and physical data
Formula	C9H11F2N3O4
Molar mass	263.198 g/mol
3D model (JSmol)	Interactive image;
	SMILES c1cn(c(=O)nc1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F;
	InChI InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1 ; Key:SDUQYLNIPVEERB-QPPQHZFASA-N ;
(verify)

ଜେମସାଇଟାବିନର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅସ୍ଥିମଜ୍ଜା ଦମନ (bone marrow suppression), ଯକୃତ ସମସ୍ୟା, ଅଇ, ଜ୍ୱର, ରାସ, ଅଣନିଶ୍ୱାସୀ ଓ କେଶହାନୀ ଆଦି ଲକ୍ଷଣ ଦେଖାଯାଏ । ଅନ୍ୟାନ୍ୟ ସାଂଘାତିକ ପ୍ରତିକ୍ରିୟାରେ ବୃକ୍‌କ ସମସ୍ୟା ଓ ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା (allergic reactions) ଦେଖାଯାଏ । ଗର୍ଭାବସ୍ଥାରେ ଦେଲେ ଏହି ଔଷଧ ଶିଶୁର ହାନୀ କରେ । ଏହା ନ୍ୟୁକ୍ଲିଓସାଇଡ ଆନାଲଗ ( nucleoside analog) ଶ୍ରେଣୀରେ ଏକ ଔଷଧ । ଏହା ଡିଏନଏ (DNA) ପ୍ରସ୍ତୁତିକୁ ଅବରୋଧ କରେ ।^[୧]

ସନ ୧୯୮୩ରେ ଜେମସାଇଟାବିନ ପେଟେଣ୍ଟ ହୋଇ ସନ ୧୯୯୫ରେ ଡାକ୍ତରୀ ବ୍ୟବ‌ହାର ନିମନ୍ତେ ସ୍ୱୀକୃତ ହୋଇଥିଲା । ^[୨] ଏହାର ନାମ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ଔଷଧ ଚିଠାରେ (World Health Organization's List of Essential Medicines) ଅଛି ଯାହା ମୌଳିକ ସ୍ୱାସ୍ଥ୍ୟ ସିସ୍ଟମ (health system) ନିମନ୍ତେ ଅତି ମହତ୍ତ୍ୱପୂର୍ଣ୍ଣ ।^[୩] ବିକାଶଶୀଳ ଦେଶମାନଙ୍କରେ (developing world) ଏହି ଔଷଧର ଏକ ଗ୍ରାମ ଭାଏଲର ହୋଲସେଲ ମୂଲ୍ୟ ୨୪.୪୧ରୁ ୩୧୬.୯୯ ଆମେରିକୀୟ ଡଲାର ।^[୪] ଇଂଲଣ୍ଡରେ ଏହାର ଭାଏଲର ଗ୍ରାମ ପିଛା ମୂଲ୍ୟ ୧୫୫ ପାଉଣ୍ଡ ।^[୫]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Gemcitabine Hydrochloride". The American Society of Health-System Pharmacists. Retrieved 8 December 2016.
↑ Fischer, Janos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 511. ISBN 9783527607495.
↑ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
↑ "Gemcitabine". International Drug Price Indicator Guide. Retrieved 8 December 2016.^{[permanent dead link]}
↑ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 590. ISBN 9780857111562.

Clinical data


Pronunciation	jem-SEYE-tə-been
Trade names	Gemzar, others
AHFS/Drugs.com	monograph
Pregnancy category	AU: D US: D (Evidence of risk)
Routes of administration	Intravenous
ATC code	L01BC05 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only ℞ (Prescription only)
Pharmacokinetic data
Protein binding	<10%
Elimination half-life	Short infusions: 32–94 minutes Long infusions: 245–638 minutes
Identifiers
IUPAC name 4-Amino-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidin-2(1H)-on
CAS Number	95058-81-4^Y
PubChem CID	60750
IUPHAR/BPS	4793
DrugBank	DB00441^Y
ChemSpider	54753^Y
UNII	B76N6SBZ8R
KEGG	D02368^Y
ChEBI	CHEBI:175901^Y
ChEMBL	CHEMBL888^Y
ECHA InfoCard	100.124.343
Chemical and physical data
Formula	C₉H₁₁F₂N₃O₄
Molar mass	263.198 g/mol
3D model (JSmol)	Interactive image
SMILES c1cn(c(=O)nc1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F
InChI InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1^Y Key:SDUQYLNIPVEERB-QPPQHZFASA-N^Y
(verify)